Non–beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma

Non–beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma

Propranolol and atenolol, current therapies for problematic infantile hemangioma (IH), are composed of R(+) and S(–) enantiomers: the R(+) enantiomer is largely devoid of beta blocker activity. We investigated the effect of R(+) enantiomers of propranolol and atenolol on the formation of IH-like blo...

Full description

Bibliographic Details
Main Authors: Bischoff, J. (Author), Fontaine, F. (Author), Francois, M. (Author), Graus, M.S (Author), Huang, L. (Author), Karnezis, T. (Author), McCann, A. (Author), Meunier, F. (Author), Mulliken, J.B (Author), Seebauer, C.T (Author), Staffa, S.J (Author), Wylie-Sears, J. (Author), Zurakowski, D. (Author)
Format: Article
Language:English
Published: American Society for Clinical Investigation 2022
Subjects:
angiogenesis
animal
animal cell
animal experiment
animal model
Animals
Article
atenolol
Atenolol
beta adrenergic receptor blocking agent
cancer stem cell
capillary hemangioma
cell differentiation
chromatin
controlled study
dexpropranolol
dimerization
drug efficacy
drug screening
enantiomer
endothelium cell
genetic transcription
hemangioma
Hemangioma
human
Humans
in vitro study
in vivo study
metabolism
Mice
molecular imaging
mouse
Neoplastic Stem Cells
neovascularization (pathology)
Neovascularization, Pathologic
nonhuman
propranolol
Propranolol
stem cell
transactivation
transcription factor Sox18
transcription initiation
tumor xenograft
vascularization
xenograft
Xenograft Model Antitumor Assays
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items